Concord Biotech Ltd. · NSE:CONCORDBIO
Concord Biotech — Q3 FY2025 Earnings Presentation
26 slides from Concord Biotech's earnings presentation, Feb 14, 2025
Slide 1: Investor Presentation intimation letter to stock exchanges
CONCORD BIOTECH LIMITED B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat. Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440 Email ID: complianceofficer@concordbiotech.com ------------------------------------------------------
Slide 2: Concord Biotech Limited Investor Presentation – February 2025
CONCORD BIOTECH Concord Biotech Limited Investor Presentation – February 2025
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Concord Biotech Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secur
Slide 4: Q3 & 9MFY25 Key Financial Highlights
Q3 & 9MFY25 Key Financial Highlights
Slide 5: Q3 & 9MFY25 Consolidated Financial Highlights
Q3 & 9MFY25 Consolidated Financial Highlights Revenue (Rs. in Crs) EBITDA (Rs. in Crs) PAT (Rs. in Crs) +10% +6% +9% 770.2 315.9 231.3 698.0 297.3 213.1 +1% -8% -2% 240.8 244.2 105.9 98.0 77.6 75.9 Q3FY24 Q3FY25 9MFY24 9MFY25 Q3FY24 Q3FY25 9MFY24 9MFY25 Q3FY24 Q3FY25 9MFY24 9MFY25 Gross Profit Margi
Slide 6: Q3 & 9MFY25 Segment wise Revenue Split
Q3 & 9MFY25 Segment wise Revenue Split API Revenue (Rs. in Crs) Formulation Revenue (Rs. in Crs) Total Revenue (Rs. in Crs) +3% +42% +10% 562.6 577.7 192.5 770.2 698.0 135.4 +3% -1% +1% 176.6 68.5 67.6 240.8 244.2 172.3 Q3FY24 Q3FY25 9MFY24 9MFY25 Q3FY24 Q3FY25 9MFY24 9MFY25 Q3FY24 Q3FY25 9MFY24 9MF
Slide 7: Q3 & 9MFY25 Geography wise Revenue Split
Q3 & 9MFY25 Geography wise Revenue Split Domestic Revenue (Rs. in Crs) Exports Revenue (Rs. in Crs) Total Revenue (Rs. in Crs) +13% +8% +10% 422.4 347.8 770.2 374.7 323.2 698.0 +1% +2% +1% 128.7 130.1 112.1 114.1 240.8 244.2 Q3FY24 Q3FY25 9MFY24 9MFY25 Q3FY24 Q3FY25 9MFY24 9MFY25 Q3FY24 Q3FY25 9MFY2
Slide 8: Management Commentary
Management Commentary Commenting on the Q3FY25 performance of the company Mr. Ankur Vaid, Joint Managing Director & Chief Executive Officer for Concord Biotech Limited said, Revenue for Q3FY25 stood at Rs. 244 crs as, a growth of 1% on a Y-o-Y basis. Our EBIDTA margins stood at 40.1%. Our Profit aft
Slide 9: Q3FY25 Consolidated Profit & Loss Account
Q3FY25 Consolidated Profit & Loss Account Profit and Loss (Rs. in Crs) Q3FY25 Q3FY24 YoY 9MFY25 9MFY24 YoY Revenue from Operations 244.2 240.8 1% 770.2 698.0 10% Cost of Goods Sold 52.4 47.1 177.0 140.4 Gross Profit 191.8 193.7 -1% 593.2 557.6 6% Gross Profit Margin 78.5% 80.4% 77.0% 79.9% Employee
Slide 10: Company Overview
Company Overview
Slide 11: Concord Biotech at a Glance
Concord Biotech at a Glance Concord Biotech Limited is a R&D driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. Key Highlights Expertise in Expertise in fermentation-based API manufacturing wit
Slide 12: Driving Innovation Through Our Expertise
Driving Innovation Through Our Expertise Fermentation Expertise Through our strong fermentation capabilities, we produce high-quality APIs, setting us apart in biotechnology and ensuring superior efficacy in medicines Mission Focus Dedicated to deliver high-quality product that enhance human health,
Slide 13: API Business Overview
API Business Overview API Overview One of the leading global developers and Focus on Niche Fermentation API’s with Diversified Product Portfolio of API’s including manufacturers of Fermentation-based APIs backward integration to Key Starting Material Immuno-suppressant, Oncology, Anti- Infectives &
Slide 14: Formulation Business Overview
Formulation Business Overview Formulation Overview Commercialization of Formulations business in Operate through B2B model across regulated Currently manufacturing Oral Solid Dosages 2016 to capitalize on the benefits of backward and emerging markets (tablets, capsules and oral suspension) integrati
Slide 15: Trusted CDMO partner for Fermentation & Semi-Synthetic API's
Trusted CDMO partner for Fermentation & Semi-Synthetic API’s CDMO Overview Prioritizes innovation, backed by a DSIR- Expertise in fermentation technology and strong Provide contract research and manufacturing R&D infrastructure enable us to undertake complex certified R&D facility with a team of 170
Slide 16: Pushing Boundaries through Manufacturing Capabilities
Pushing Boundaries through Manufacturing Capabilities Unit I (API) – Dholka, Gujarat Unit II (Formulations) – Valthera, Gujarat FY2000 Operations commenced FY2016 Operations commenced 112302 sq.m. Spread across 94826 sq.m. Spread across 450 m3 Installed capacity 802Mn Units Installed capacity Unit I
Slide 17: Pioneering R&D Capabilities
Pioneering R&D Capabilities R&D Initiatives: State-of-the-Art Facilities: Where Ideas Materialise 173 6/4 R&D Employee ANDA approved products/ API R&DLab Strength PARA IV Approvals Cost Improvement • Specialized capabilities for isolation of strains, mutation, and passive selection of microbial stra
Slide 18: DMF Filings Across Geographies
DMF Fillings Across Geographies Molecules US EU Canada Japan China Tacrolimus Mycophenolate Mofetil Suppressants Immuno- Mycophenolate Sodium Cyclosporine Sirolimus Pimecrolimus Temsirolimus Everolimus Oncology Romidepsin Mitomycin Dact
Slide 19: Wide Range of Formulation Product Portfolio for Overseas Markets
Wide Range of Formulation Product Portfolio for Overseas Markets Regulated Markets Emerging Markets Product Name ANDA Approval Product Name Mycophenolate Mofetil Capsules Mycophenolate Mofetil Capsules Mycophenolate Mofetil Tablets Mycophenolate Mofetil Suspension Mycophenolic Acid DR Tablets USP My
Slide 20: Diversified Customer Base
Diversified Customer Base New Customer Addition / Product Addition in Existing Customers 95 63 47 48 47 FY20 FY21 FY22 FY23 FY24 Reducing Customer Concentration % Contribution from Top 10 Customers FY24 42.0% 70+ Countries 44.3% FY23 47.7% FY22 Worldwide Presence Tailored Distribution Models 48.2% F
Slide 21: Paving the Way for Sustainability
Paving the Way for Sustainability Our Vision for Sustainability The Path of Sustainability Sustainable Manufacturing Research & Development Efficient Resource Management Global Green Leadership Constant Improvement & Adaptation Environmental Conservation Awarded Bronze Medal by EcoVadis Our Initiati
Slide 22: Key Business Differentiators
Key Business Differentiators
Slide 23: End-to-End Expertise in Complex Fermentation Value Chain
End-to-End Expertise in Complex Fermentation Value Chain Overview of Integrated Platform Leadership Position 1250 M3 Leadership position for select molecules Fermentation Capacity across two in global markets API facilities R&D Patents 01 02 03 04 Key Starting Material API Manufacturing Over 2 Decad
Slide 24: Constructing Formidable Barriers to Entry
Constructing Formidable Barriers to Entry Significant Capital Intensive Operational Complex Process & Infrastructural Requirements Long gestation Period Entry Barriers Technical Expertise Requirements (large scale fermenters) Complex technical capabilities, difficulties in scaling up operations and
Slide 25: Key Growth Drivers
Key Growth Drivers API Business Expanding API Marketing existing APIs Increasing wallet share Portfolio to new customers with existing customers 01 Formulations Business CONCORD BIOTECH Expanding portfolio through own development & in- Launching new dosage forms including Expanding geographic reach
Slide 26: For further Information, please contact
For further Information, please contact Company: Investor Relations Advisor: Concord Biotech Limited Strategic Growth Advisors Pvt. Ltd. CIN: L24230GJ1984PLC007440 CIN - U74140MH2010PTC204285 Mr. Lalit Sethi – Chief Financial Officer lalitsethi@concordbiotech.com Mr. Jigar Kavaiya / Mr. Sagar Shroff